Improvement of Obesity by Activation of I1-Imidazoline Receptors in High Fat Diet-fed Mice

H. H. Chung; J.- T. Cheng

doi:10.1055/s-0033-1334946

Hormone and Metabolic Research, Table of Contents

Horm Metab Res 2013; 45(08): 581-585
DOI: 10.1055/s-0033-1334946

Original Basic

Improvement of Obesity by Activation of I₁-Imidazoline Receptors in High Fat Diet-fed Mice

H. H. Chung

¹Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City, Taiwan

,

J.- T. Cheng

¹Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City, Taiwan

²Institute of Medical Science, College of Health Science, Chang Jung Christian University, Guei-Ren, Tainan City, Taiwan

› Author Affiliations

Abstract

Imidazoline I₁-receptor (I₁R) is known to regulate the blood pressure, and rilmenidine, as the agonist, is used to treat hypertension in clinics. However, the role of I₁R in obesity is still unclear. In the present study, we investigated the changes of obesity by activation of I₁R in high fat diet (HFD)-fed mice. Chronic administration of rilmenidine into HFD-fed mice for 8 weeks significantly reduced body weight, which was reversed by efaroxan at the dose sufficient to block I₁R. Also, rilmenidine significantly decreased the energy intake of HFD-fed mice. This reduction of energy intake was abolished by efaroxan at the same dosing for blockade of I₁R. However, hypothalamic I₁R protein expression in HFD-fed mice was markedly lower than that in normal chow-fed mice. In addition, epididymal white adipose tissue (eWAT) cell size in HFD-fed mice was decreased by rilmenidine via the activation of I₁R. Moreover, effect of rilmenidine on appetite disappeared in db/db mice. Taken together, we suggest that rilmenidine can improve obesity in HFD-fed mice through an activation of I₁R to ameliorate energy intake and eWAT accumulation.

Key words

energy intake - high fat diet-induced mice - hyperphagia - imidazoline I₁-receptors

Full Text

References

References
1 Barness LA, Opitz JM, Gilbert-Barness E. Obesity: genetic, molecular, and environmental aspects. Am J Med Genet A 2007; 143A: 3016-3034
2 Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209
3 Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007; 176: S1-S13
4 Strychar I. Diet in the management of weight loss. CMAJ 2006; 174: 56-63
5 Miller GD. Improved nutrient intake in older obese adults undergoing a structured diet and exercise intentional weight loss program. J Nutr Health Aging 2010; 14: 461-466
6 MacLean PS, Higgins JA, Wyatt HR, Melanson EL, Johnson GC, Jackman MR, Giles ED, Brown IE, Hill JO. Regular exercise attenuates the metabolic drive to regain weight after long-term weight loss. Am J Physiol Regul Integr Comp Physiol 2009; 297: R793-R802
7 Ernsberger P, Friedman JE, Koletsky RJ. The I1-imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens 1997; 15 (Suppl) S9-S23
8 Koletsky RJ, Velliquette RA, Ernsberger P. The role of I(1)-imidazoline receptors and alpha(2)-adrenergic receptors in the modulation of glucose and lipid metabolism in the SHROB model of metabolic syndrome X. Ann N Y Acad Sci 2003; 1009: 251-261
9 Niu CS, Wu HT, Cheng KC, Lin KC, Chen CT, Cheng JT. A novel mechanism for decreasing plasma lipid level from imidazoline I-1 receptor activation in high fat diet-fed mice. Horm Metab Res 2011; 43: 458-463
10 Dupuy O, Bauduceau B, Mayaudon H. Efficacy of rilmenidine, a selective I1 imidazoline receptor binding agent in diabetic hypertensive patients. Am J Hypertens 2000; 13: 123S-126S
11 Meredith PA, Reid JL. Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients. A retrospective analysis of a general practice study. Am J Cardiovasc Drugs 2004; 4: 195-200
12 Velliquette RA, Kossover R, Previs SF, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 300-312
13 Yang PS, Wu HT, Chung HH, Chen CT, Chi CW, Yeh CH, Cheng JT. Rilmenidine improves hepatic steatosis through p38-dependent pathway to higher the expression of farnesoid X receptor. Naunyn Schmiedebergs Arch Pharmacol 2012; 385: 51-56
14 Chung HH, Yang TT, Chen MF, Chou MT, Cheng JT. Improvement of hyperphagia by activation of cerebral I(1)-imidazoline receptors in streptozotocin-induced diabetic mice. Horm Metab Res 2012; 44: 645-649
15 Gongadze NV, Antelava NA, Kezeli TD. Imidazoline receptors. Georgian Med News 2008; 44-47
16 Head GA, Mayorov DN. Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents Med Chem 2006; 4: 17-32
17 Head GA, Burke SL, Chan CK. Site and receptors involved in the sympathoinhibitory actions of rilmenidine. J Hypertens 1998; 16 (Suppl) S7-S12
18 Ko WC, Liu IM, Chung HH, Cheng JT. Activation of I(2)-imidazoline receptors may ameliorate insulin resistance in fructose-rich chow-fed rats. Neurosci Lett 2008; 448: 90-93
19 Su CH, Liu IM, Chung HH, Cheng JT. Activation of I2-imidazoline receptors by agmatine improved insulin sensitivity through two mechanisms in type-2 diabetic rats. Neurosci Lett 2009; 457: 125-128
20 Yang TT, Ku PM, Hsu CT, Chung HH, Lee WJ, Cheng JT. Mediation of AMP Kinase in the Increase of Glucose Uptake in L6 Cells Induced by Activation of Imidazoline I-2 Receptors. Horm Metab Res 2012; Dec 7. [Epub ahead of print]
21 Morgan NG, Chan SL. Imidazoline binding sites in the endocrine pancreas: can they fulfil their potential as targets for the development of new insulin secretagogues?. Curr Pharm Des 2001; 7: 1413-1431
22 Anderson NJ, Lupo PA, Nutt DJ, Hudson AL, Robinson ES. Characterisation of imidazoline I2 binding sites in pig brain. Eur J Pharmacol 2005; 519: 68-74
23 Thomas AJ, Erokwu BO, Yamamoto BK, Ernsberger P, Bishara O, Strohl KP. Alterations in respiratory behavior, brain neurochemistry and receptor density induced by pharmacologic suppression of sleep in the neonatal period. Brain Res Dev Brain Res 2000; 120: 181-189
24 Zhang J, Abdel-Rahman AA. Mitogen-activated protein kinase phosphorylation in the rostral ventrolateral medulla plays a key role in imidazoline (i1)-receptor-mediated hypotension. J Pharmacol Exp Ther 2005; 314: 945-952
25 El-Mas MM, El-Gowelli HM, Ghazal AR, Harraz OF, Mohy El-Din MM. Facilitation of central imidazoline I(1)-site/extracellular signal-regulated kinase/p38 mitogen-activated protein kinase signalling mediates the hypotensive effect of ethanol in rats with acute renal failure. Br J Pharmacol 2009; 158: 1629-1640
26 El-Mas MM, Abdel-Rahman AA. Evidence for the involvement of central I1 imidazoline receptor in ethanol counteraction of clonidine hypotension in spontaneously hypertensive rats. J Cardiovasc Pharmacol 2001; 38: 417-426
27 Bing C, King P, Pickavance L, Brown M, Ziegler D, Kaan E, Williams G. The effect of moxonidine on feeding and body fat in obese Zucker rats: role of hypothalamic NPY neurones. Br J Pharmacol 1999; 127: 35-42
28 Sato C, Shikata K, Hirota D, Sasaki M, Nishishita S, Miyamoto S, Kodera R, Ogawa D, Tone A, Kataoka HU, Wada J, Kajitani N, Makino H. P-selectin glycoprotein ligand-1 deficiency is protective against obesity-related insulin resistance. Diabetes 2011; 60: 189-199
29 Gautron L, Elmquist JK. Sixteen years and counting: an update on leptin in energy balance. J Clin Invest 2011; 121: 2087-2093
30 Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL, Caro JF. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996; 334: 292-295
31 Varela L, Horvath TL. Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis. EMBO Rep 2012; 13: 1079-1086
32 Glavas MM, Kirigiti MA, Xiao XQ, Enriori PJ, Fisher SK, Evans AE, Grayson BE, Cowley MA, Smith MS, Grove KL. Early overnutrition results in early-onset arcuate leptin resistance and increased sensitivity to high-fat diet. Endocrinology 2010; 151: 1598-1610
33 Veniant MM, LeBel CP. Leptin: from animals to humans. Curr Pharm Des 2003; 9: 811-818
34 Sanjuliani AF, de Abreu VG, Francischetti EA. Selective imidazoline agonist moxonidine in obese hypertensive patients. Int J Clin Pract 2006; 60: 621-629
35 Jequier E. Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 2002; 967: 379-388
36 Guan XM, Yu H, Trumbauer M, Frazier E, Van der Ploeg LH, Chen H. Induction of neuropeptide Y expression in dorsomedial hypothalamus of diet-induced obese mice. Neuroreport 1998; 9: 3415-3419
37 Fellmann L, Nascimento AR, Tibiriça E, Bousquet P. Murine models for pharmacological studies of the metabolic syndrome. Pharmacol Ther 2013; 137: 331-340
38 Bergen HT, Mizuno TM, Taylor J, Mobbs CV. Hyperphagia and weight gain after gold-thioglucose: relation to hypothalamic neuropeptide Y and proopiomelanocortin. Endocrinology 1998; 139: 4483-4488
39 Zammaretti F, Panzica G, Eva C. Fasting, leptin treatment, and glucose administration differentially regulate Y(1) receptor gene expression in the hypothalamus of transgenic mice. Endocrinology 2001; 142: 3774-3782
40 Volkoff H, Eykelbosh AJ, Peter RE. Role of leptin in the control of feeding of goldfish Carassius auratus: interactions with cholecystokinin, neuropeptide Y and orexin A, and modulation by fasting. Brain Res 2003; 972: 90-109
41 Xu B, Kalra PS, Farmerie WG, Kalra SP. Daily changes in hypothalamic gene expression of neuropeptide Y, galanin, proopiomelanocortin, and adipocyte leptin gene expression and secretion: effects of food restriction. Endocrinology 1999; 140: 2868-2875
42 Wang JH, Wang F, Yang MJ, Yu DF, Wu WN, Liu J, Ma LQ, Cai F, Chen JG. Leptin regulated calcium channels of neuropeptide Y and proopiomelanocortin neurons by activation of different signal pathways. Neuroscience 2008; 156: 89-98
43 Arora S Anubhuti Role of neuropeptides in appetite regulation and obesity – a review. Neuropeptides 2006; 40: 375-401